Active substance
Results for the substance brexucabtagen autoleucel
1 result
About this active substance
Brexucabtagene autoleucel is a cell-based gene therapy used for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. It is a CAR-T (chimeric antigen receptor T-cell) therapy that involves genetically modifying the patient's T-cells to recognize and destroy cancer cells.
The treatment is administered via intravenous infusion after a procedure to collect and modify the patient's T-cells. The process requires hospitalization and close monitoring to manage potential side effects.
Common side effects include cytokine release syndrome, fever, fatigue, nausea, and decreased blood cell counts. In rare cases, neurotoxicity or severe infections may occur.
Brexucabtagene autoleucel is not recommended for pregnant or breastfeeding women. Patients should inform their doctor of their full medical history and any other medications being used before starting treatment.
The treatment is administered via intravenous infusion after a procedure to collect and modify the patient's T-cells. The process requires hospitalization and close monitoring to manage potential side effects.
Common side effects include cytokine release syndrome, fever, fatigue, nausea, and decreased blood cell counts. In rare cases, neurotoxicity or severe infections may occur.
Brexucabtagene autoleucel is not recommended for pregnant or breastfeeding women. Patients should inform their doctor of their full medical history and any other medications being used before starting treatment.